NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROCKLATAN is a fixed-dose combination ophthalmic solution containing netarsudil (0.02%) and latanoprost (0.005%), approved by the FDA in March 2019. It combines a Rho kinase inhibitor with a prostaglandin analog to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The dual mechanism provides additive IOP-lowering effects, offering a convenient once-daily dosing option that consolidates two separate medications into a single drop.
$0.1BPart D
7.9 years to LOEMechanism of Action
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Rocklatan Retinal Perfusion OCT Study
Started Jan 2026
30 enrolled
Glaucoma
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Started Nov 2025
30 enrolled
Open Angle GlaucomaOcular Hypertension
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Started Sep 2025
489 enrolled
Ocular HypertensionOpen Angle Glaucoma
Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
Started Feb 2025
70 enrolled
Glaucoma
Next Generation Rocklatan
Started Sep 2024
426 enrolled
Open Angle GlaucomaOcular Hypertension
Worked on ROCKLATAN at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.